Literature DB >> 14679016

Biological significance of aminopeptidase N/CD13 in thyroid carcinomas.

Astrid Kehlen1, Uwe Lendeckel, Henning Dralle, Jürgen Langner, Cuong Hoang-Vu.   

Abstract

Aminopeptidase N (APN)/CD13 is a transmembrane ectopeptidase expressed on a wide variety of cells. However, the precise function of APN/CD13 in tumor cells and the relationship of APN/CD13 to thyroid cancer remain unclear. In our study, we quantified the expression of APN/CD13 and additionally dipeptidyl peptidase IV (DPIV)/CD26 in thyroid carcinoma cell lines and in tissues of patients with thyroid carcinomas. Undifferentiated anaplastic thyroid carcinomas expressed more APN/CD13 than differentiated thyroid carcinomas. DPIV/CD26 showed an opposite expression pattern. We detected higher levels of DPIV/CD26 in follicular thyroid carcinomas (FTCs) and papillary thyroid carcinomas than in undifferentiated anaplastic thyroid carcinomas. In the undifferentiated thyroid carcinoma cell line 1736, APN/CD13 mRNA expression could be increased by epidermal growth factor, basic fibroblast growth factor, interleukin-6, and tumor necrosis factor alpha. FTC-133 cells stably transfected with an expression vector for APN-enhanced green fluorescent protein showed a higher migration rate than FTC-133 cells transfected with the enhanced green fluorescent protein-control plasmid. Overexpression of APN/CD13 in stably transfected cells is associated with down-regulation of N-myc down-regulated gene (NDRG)-1, melanoma-associated antigen ME491/CD63, and DPIV/CD26 gene expression. Inhibition of APN/CD13 mRNA expression by small interfering RNA induced NDRG-1, ME491/CD63, and DPIV/CD26 mRNA expression in cells of the undifferentiated thyroid carcinoma cell line C643. We conclude that APN/CD13-associated down-regulation of NDRG-1, ME491/CD63, and DPIV/CD26 in thyroid carcinoma cells is an important step of tumor progression to more malignant phenotypes, and we underline the important role of APN/CD13 as mediator in a multimolecular process regulating cell migration.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14679016

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  36 in total

1.  Structure and activity of CPNGRC: a modified CD13/APN peptidic homing motif.

Authors:  Leigh A Plesniak; Bridget Salzameda; Holly Hinderberger; Elizabeth Regan; James Kahn; Stephen A Mills; Peter Teriete; Yong Yao; Patricia Jennings; Francesca Marassi; Joseph A Adams
Journal:  Chem Biol Drug Des       Date:  2010-03-30       Impact factor: 2.817

2.  Cooperative effects of aminopeptidase N (CD13) expressed by nonmalignant and cancer cells within the tumor microenvironment.

Authors:  Liliana Guzman-Rojas; Roberto Rangel; Ahmad Salameh; Julianna K Edwards; Eleonora Dondossola; Yun-Gon Kim; Alan Saghatelian; Ricardo J Giordano; Mikhail G Kolonin; Fernanda I Staquicini; Erkki Koivunen; Richard L Sidman; Wadih Arap; Renata Pasqualini
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

3.  Differential exoprotease activities confer tumor-specific serum peptidome patterns.

Authors:  Josep Villanueva; David R Shaffer; John Philip; Carlos A Chaparro; Hediye Erdjument-Bromage; Adam B Olshen; Martin Fleisher; Hans Lilja; Edi Brogi; Jeff Boyd; Marta Sanchez-Carbayo; Eric C Holland; Carlos Cordon-Cardo; Howard I Scher; Paul Tempst
Journal:  J Clin Invest       Date:  2006-01       Impact factor: 14.808

4.  Gemigliptin, a novel dipeptidyl peptidase-IV inhibitor, exerts a synergistic cytotoxicity with the histone deacetylase inhibitor PXD101 in thyroid carcinoma cells.

Authors:  S H Kim; J G Kang; C S Kim; S-H Ihm; M G Choi; H J Yoo; S J Lee
Journal:  J Endocrinol Invest       Date:  2017-11-16       Impact factor: 4.256

5.  Prognostic value of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9) and aminopeptidase N/CD13 in breast cancer patients.

Authors:  Irena Ranogajec; Jasminka Jakić-Razumović; Velibor Puzović; Jelka Gabrilovac
Journal:  Med Oncol       Date:  2011-05-25       Impact factor: 3.064

6.  LYP, a novel bestatin derivative, inhibits cell growth and suppresses APN/CD13 activity in human ovarian carcinoma cells more potently than bestatin.

Authors:  Jian-Jun Gao; Zu-Hua Gao; Cui-Rong Zhao; Yi Yuan; Shu-Xiang Cui; Xiao-Fan Zhang; Yan-Na Cheng; Wen-Fang Xu; Wei Tang; Xian-Jun Qu
Journal:  Invest New Drugs       Date:  2010-01-29       Impact factor: 3.850

7.  Synergistic cytotoxicity of the dipeptidyl peptidase-IV inhibitor gemigliptin with metformin in thyroid carcinoma cells.

Authors:  Si Hyoung Kim; Jun Goo Kang; Chul Sik Kim; Sung-Hee Ihm; Moon Gi Choi; Hyung Joon Yoo; Seong Jin Lee
Journal:  Endocrine       Date:  2017-12-28       Impact factor: 3.633

8.  The X-ray crystal structure of human aminopeptidase N reveals a novel dimer and the basis for peptide processing.

Authors:  Alan H M Wong; Dongxia Zhou; James M Rini
Journal:  J Biol Chem       Date:  2012-08-29       Impact factor: 5.157

9.  Decrease in dipeptidyl peptidase IV activity is linked to the efficacy of differentiating compounds in follicular thyroid carcinoma cell lines.

Authors:  E Fröhlich; E Engel; R Wahl
Journal:  Horm Metab Res       Date:  2011-03-16       Impact factor: 2.936

10.  Exploring ligand dissociation pathways from aminopeptidase N using random acceleration molecular dynamics simulation.

Authors:  Ya Liu; GuoGang Tu; XiaoPing Lai; BinHai Kuang; ShaoHua Li
Journal:  J Mol Model       Date:  2016-09-13       Impact factor: 1.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.